Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): The DERIVE Study

P Fioretto, S Del Prato, JB Buse… - Diabetes, Obesity …, 2018 - Wiley Online Library
Aims Dapagliflozin is a selective inhibitor of sodium glucose co‐transporter 2 (SGLT2). This
study assessed the efficacy and safety of dapagliflozin 10 mg vs placebo in patients with …
被引用次数：180 相关文章
[PDF] archive.org

[PDF][PDF] Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): The DERIVE Study

MD Stefano Del Prato - Diabetes Obes Metab, 2018 - scholar.archive.org
Aims: Dapagliflozin is a selective inhibitor of sodium glucose co-transporter 2 (SGLT2). This
study assessed the efficacy and safety of dapagliflozin 10 mg vs placebo in patients with …

Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): The DERIVE Study

P Fioretto, S Del Prato, JB Buse… - Diabetes, Obesity and …, 2018 - cdr.lib.unc.edu
Aims: Dapagliflozin is a selective inhibitor of sodium glucose co-transporter 2 (SGLT2). This
study assessed the efficacy and safety of dapagliflozin 10 mg vs placebo in patients with …
[PDF] core.ac.uk

[PDF][PDF] Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): The DERIVE Study

MD Stefano Del Prato - Diabetes Obes Metab, 2018 - core.ac.uk
Aims: Dapagliflozin is a selective inhibitor of sodium glucose co-transporter 2 (SGLT2). This
study assessed the efficacy and safety of dapagliflozin 10 mg vs placebo in patients with …

Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): The DERIVE Study

P Fioretto, S Del Prato, JB Buse… - DIABETES, OBESITY …, 2018 - ricerca.uniba.it
Aims: Dapagliflozin is a selective inhibitor of sodium glucose co-transporter 2 (SGLT2). This
study assessed the efficacy and safety of dapagliflozin 10 mg vs placebo in patients with …
[HTML] nih.gov

[HTML][HTML] Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): The DERIVE Study

P Fioretto, S Del Prato, JB Buse… - Diabetes, Obesity & …, 2018 - ncbi.nlm.nih.gov
Aims Dapagliflozin is a selective inhibitor of sodium glucose co‐transporter 2 (SGLT2). This
study assessed the efficacy and safety of dapagliflozin 10 mg vs placebo in patients with …

[引用][C] Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): The DERIVE Study

P Fioretto, S Del Prato, JB Buse, R Goldenberg… - Diabetes, Obesity and …, 2018 - cir.nii.ac.jp
Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal
impairment (chronic kidney disease stage 3A): The DERIVE Study | CiNii Research CiNii 国立 …
[PDF] unipd.it

[PDF][PDF] Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): The DERIVE Study

P Fioretto, S Del Prato, JB Buse… - DIABETES, OBESITY …, 2018 - research.unipd.it
Aims: Dapagliflozin is a selective inhibitor of sodium glucose co-transporter 2 (SGLT2). This
study assessed the efficacy and safety of dapagliflozin 10 mg vs placebo in patients with …

Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): The DERIVE Study

P Fioretto, S Del Prato, JB Buse… - Diabetes, obesity & …, 2018 - pubmed.ncbi.nlm.nih.gov
Aims Dapagliflozin is a selective inhibitor of sodium glucose co-transporter 2 (SGLT2). This
study assessed the efficacy and safety of dapagliflozin 10 mg vs placebo in patients with …

Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): The DERIVE Study

P Fioretto, S Del Prato, JB Buse… - Diabetes, obesity and …, 2018 - diva-portal.org
Aims: Dapagliflozin is a selective inhibitor of sodium glucose co-transporter 2 (SGLT2). This
study assessed the efficacy and safety of dapagliflozin 10 mg vs placebo in patients with …